# Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada

> **NCT07718139** · — · ACTIVE_NOT_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 300 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** nivolumab
- **BIOLOGICAL:** pembrolizumab
- **BIOLOGICAL:** durvalumab

## Key facts

- **NCT ID:** NCT07718139
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-02-28
- **Primary completion:** 2026-09-30
- **Final completion:** 2027-03-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07718139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07718139, "Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07718139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*